Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 7/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445972 | 0.80 | FOLH1 (0.59) | FOLH1SLC16A3CLCN2TSHRHTT | |
| SCHEMBL27558796 | 0.79 | SSTR4 (0.51) | ALDH1A1ADRB2CYP2C9 | |
| SCHEMBL27965407 | 0.79 | FOLH1 (0.58) | FOLH1SLC16A3CLCN2TSHRHTT | |
| SCHEMBL28359199 | 0.76 | FOLH1 (0.54) | FOLH1SLC16A3CLCN2TSHRHTT | |
| SCHEMBL11228089 | 0.75 | FOLH1 (0.53) | FOLH1SLC16A3CLCN2TSHRHTT | |
| SCHEMBL30365583 | 0.74 | FOLH1 (0.76) | FOLH1SLC16A3TSHRHTTHIF1A | |
| SCHEMBL70392 | 0.74 | FOLH1 (0.76) | FOLH1SLC16A3TSHRHTTHIF1A | |
| SCHEMBL28362576 | 0.74 | FOLH1 (0.51) | FOLH1SLC16A3CLCN2TSHRHTT | |
| SCHEMBL24072616 | 0.74 | FOLH1 (0.59) | FOLH1SLC16A3TSHRHTTHIF1A | |
| SCHEMBL28492838 | 0.73 | FOLH1 (0.54) | FOLH1SLC16A3CLCN2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1242400-B1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
| US-6998416-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2004-08-05 | — | — | US | disclosed |
| US-6716871-B2 | OBESITY; INFLAMMATORY DISEASES, DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, CENTRAL NERVOUS SYSTEM DISORDERS; 3-HYDROXYALKYL-4-DIALKOXYPHENYL-SUBSTITUTED PYRROLIDINES | ICOS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-6423710-B1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE7A | FOLH1 891/4885SLC16A3 4209/4885CLCN2 4092/4885 |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | FOLH1 891/4885SLC16A3 4209/4885CLCN2 4092/4885 |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | FOLH1 891/4885SLC16A3 4209/4885CLCN2 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.